Compare SELX & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SELX | NSRX |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | Taiwan | Israel |
| Employees | N/A | 7 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0M | 25.8M |
| IPO Year | 2023 | N/A |
| Metric | SELX | NSRX |
|---|---|---|
| Price | $0.44 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 3.3M | 93.3K |
| Earning Date | 05-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $1.98 |
| 52 Week High | $1.85 | $9.99 |
| Indicator | SELX | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 58.74 |
| Support Level | $0.32 | $2.04 |
| Resistance Level | $0.78 | $5.20 |
| Average True Range (ATR) | 0.06 | 0.38 |
| MACD | 0.01 | 0.26 |
| Stochastic Oscillator | 53.08 | 61.51 |
Semilux International Ltd is a company that operates through its subsidiaries which is an optical and 3D sensing technology company that is involved in the customization, design and supply of optical components and integrated chip for various industries including autonomous driving, intelligent lighting, as well as unmanned aerial vehicles. In collaboration with its clients, TCO conceptualizes and produces high precision optics and sensing modules that are specifically customized to clients' needs for ease of integration in overall design and production. Applications for TCO's products include automotive laser headlight systems, adaptive driving beams (ADB) as well as light detection and autonomous driving systems (LiDAR).
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.